中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.019 seconds)

    Treatment of idiopathic pulmonary fibrosis
    1.
    发明授权
    Treatment of idiopathic pulmonary fibrosis 有权

    公开(公告)号：US12213961B2

    公开(公告)日：2025-02-04

    申请号：US18513181

    申请日：2023-11-17

    Applicant: VICORE PHARMA AB

    Inventor： Carl-Johan Dalsgaard ,  Rohit Batta

    IPC: A61K31/4178 ,  A61K9/48 ,  A61P1/00 ,  A61P11/00

    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

    NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST
    2.
    发明申请
    NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST 有权

    公开(公告)号：US20210386712A1

    公开(公告)日：2021-12-16

    申请号：US17458886

    申请日：2021-08-27

    Applicant: VICORE PHARMA AB

    Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

    IPC: A61K31/4178 ,  A61K38/21 ,  A61K31/513 ,  A61K31/706 ,  A61P31/14 ,  A61K31/573 ,  A61K31/16 ,  A61K45/06 ,  A61K31/7056

    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-thiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

    NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST
    4.
    发明申请
    NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST 有权

    公开(公告)号：US20210290596A1

    公开(公告)日：2021-09-23

    申请号：US17113416

    申请日：2020-12-07

    Applicant: Vicore Pharma AB

    Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

    IPC: A61K31/4178 ,  A61K45/06 ,  A61K31/573 ,  A61K38/21 ,  A61K31/706 ,  A61K31/16 ,  A61K31/7056 ,  A61K31/513 ,  A61P31/14

    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

    Use of angiotensin II type 2 receptor agonist
    6.
    发明授权
    Use of angiotensin II type 2 receptor agonist 有权

    公开(公告)号：US11123329B1

    公开(公告)日：2021-09-21

    申请号：US17113416

    申请日：2020-12-07

    Applicant: Vicore Pharma AB

    Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

    IPC: A61K31/4178 ,  A61P31/14 ,  A61K31/16 ,  A61K31/573 ,  A61K38/21 ,  A61K45/06 ,  A61K31/513 ,  A61K31/7056 ,  A61K31/706

    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

Patent Agency Ranking